513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Re-Stimulated Tumor-Infiltrating Lymphocytes Ovarian Cancer	University Health Network, Toronto	P1	CC (43)
Retlirafusp Alfa Ovarian Cancer	Qinglei Gao	P2	CC (43)
Riluzole Ovarian Cancer	University of California, Irvine	P2	CC (43)
Romiplostim Ovarian Cancer	Peking University People's Hospital	P2	CC (43)
Sctil Ovarian Cancer	Peking Union Medical College Hospital	P2	CC (43)
Sleeping Beauty Transposed Pbl Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Tart Cherry Ovarian Cancer	University of California, Davis	P2	CC (43)
Tcr Transduced T-Cells Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Tegtociclib Ovarian Cancer	Pfizer	P2	CC (43)
Telmisartan Ovarian Cancer	Tyler J Curiel	P2	CC (43)
Tretinoin Ovarian Cancer	Peking University People's Hospital	P2	CC (43)
Tuvusertib Ovarian Cancer	EMD Serono Research & Development Institute, Inc.	P2	CC (43)
Ucmym802 Ovarian Cancer	UTC Therapeutics Inc.	P1	CC (43)
Utidelone Ovarian Cancer	Beijing Biostar Pharmaceuticals Co., Ltd.	P2	CC (43)
uv1 Ovarian Cancer	Nordic Society of Gynaecological Oncology - Clinical Trials Unit	P2	CC (43)
Valemetostat Ovarian Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P2	CC (43)
Volrustomig Ovarian Cancer	AstraZeneca	P2	CC (43)
Yangzheng Xiaoji Ovarian Cancer	Sichuan Cancer Hospital and Research Institute	P2	CC (43)
Zanidatamab Ovarian Cancer	Jazz Pharmaceuticals	P2	CC (43)
αdc1 vaccine Ovarian Cancer	Kalinski, Pawel, MD, PhD	P2	CC (43)
e-602 Ovarian Cancer	Palleon Pharmaceuticals, Inc.	P1/2	CC (42)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-5901 (99.0%) -(Ighd) -Ighj302 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-1101 (96.8%) -Igkj401 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa Ovarian Cancer	Kineta Inc.	P1/2	CC (42)
il15-transpresenting wt1-targeted dendritic cell vaccine Ovarian Cancer	University Hospital, Antwerp	P1/2	CC (42)
Nelfinavir Ovarian Cancer	Medical University of South Carolina	P2	CC (42)
Rintatolimod Ovarian Cancer	Kalinski, Pawel, MD, PhD	P2	CC (42)
sl-172154 Ovarian Cancer	Shattuck Labs, Inc.	P1	CC (42)
Ctim-76 Ovarian Cancer	Context Therapeutics Inc.	P1	CC (41)
Cytokine-Induced Memory-Like Natural Killer Cells Ovarian Cancer	Dana-Farber Cancer Institute	P1	CC (41)
Drug Product De-Til-0255 Ovarian Cancer	Nurix Therapeutics, Inc.	P1	CC (41)
gb-5267 - iv only Ovarian Cancer	Roswell Park Cancer Institute	P1	CC (41)
hs-20093 Ovarian Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	CC (41)
Lunresertib Ovarian Cancer	University Health Network, Toronto	P1	CC (41)
lyl797 Ovarian Cancer	Lyell Immunopharma, Inc.	P1	CC (41)
men2501 Ovarian Cancer	Stemline Therapeutics, Inc.	P1	CC (41)
MGC026 Ovarian Cancer	MacroGenics	P1	CC (41)
Nirogacestat Ovarian Cancer	SpringWorks Therapeutics, Inc.	P2	CC (41)
Tulmimetostat Ovarian Cancer	Lan Coffman	P1	CC (41)
[111in]-fpi-1967 Ovarian Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
177lu-betabart Ovarian Cancer	Radiopharm Theranostics, Ltd	P1/2	CC (40)
[203pb]pb-psv359 Ovarian Cancer	Perspective Therapeutics	P1/2	CC (40)
[212pb]pb-psv359 Ovarian Cancer	Perspective Therapeutics	P1/2	CC (40)
[225Ac]-FPI-1966 Ovarian Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
a2b543 Ovarian Cancer	A2 Biotherapeutics Inc.	P1/2	CC (40)
a2b694 Ovarian Cancer	A2 Biotherapeutics Inc.	P1/2	CC (40)
Ace-86225106 Ovarian Cancer	Acerand Therapeutics (Shanghai) Limited	P1/2	CC (40)
Acetylcysteine Ovarian Cancer	University of California, Irvine	P1/2	CC (40)
Alnodesertib Ovarian Cancer	Artios Pharma Ltd	P1/2	CC (40)
Amxi-5001 Ovarian Cancer	AtlasMedx, Incorporated	P1/2	CC (40)
Anti-Hcd70 Car Transduced Pbl Ovarian Cancer	National Cancer Institute (NCI)	P1/2	CC (40)
Anti-Mesothelin Chimeric T Cell Receptor Transduced Peripheral Blood Lymphocytes Ovarian Cancer	Weijia Fang, MD	P1/2	CC (40)

Showing 251 to 300 of 513 assets

PreviousPage 6 of 11Next